Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,033,782
  • Shares Outstanding, K 85,353
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • EBIT $ -332 M
  • EBITDA $ -313 M
  • 60-Month Beta 1.67
  • Price/Sales 10.80
  • Price/Cash Flow N/A
  • Price/Book 2.06

Options Overview Details

View History
  • Implied Volatility 59.26% ( +1.10%)
  • Historical Volatility 52.61%
  • IV Percentile 48%
  • IV Rank 31.51%
  • IV High 89.11% on 12/07/23
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 2,783
  • Volume Avg (30-Day) 7,713
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 74,686
  • Open Int (30-Day) 70,299

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.23
  • Number of Estimates 12
  • High Estimate -0.63
  • Low Estimate -1.93
  • Prior Year 1.10
  • Growth Rate Est. (year over year) -211.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.44 +4.56%
on 10/23/24
59.07 -19.57%
on 11/11/24
-1.00 (-2.06%)
since 10/21/24
3-Month
43.42 +9.42%
on 09/06/24
59.07 -19.57%
on 11/11/24
-2.48 (-4.96%)
since 08/21/24
52-Week
43.42 +9.42%
on 09/06/24
91.10 -47.85%
on 02/22/24
-20.06 (-29.69%)
since 11/21/23

Most Recent Stories

More News
Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

GH : 30.57 (-0.36%)
CRSP : 46.10 (-2.45%)
TSLA : 343.49 (+0.43%)
PACB : 1.75 (+1.74%)
TTD : 123.49 (-0.33%)
U : 21.93 (+1.39%)
MRNA : 36.56 (-1.03%)
AMZN : 200.66 (-1.09%)
COIN : 307.98 (-3.76%)
SQ : 90.12 (+0.47%)
PLTR : 62.58 (+0.74%)
ARKK : 55.04 (-0.43%)
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.

CRSP : 46.10 (-2.45%)
IOVA : 8.09 (-0.61%)
VRTX : 448.31 (-0.65%)
Where Will CRISPR Therapeutics Be in 3 Years?

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes...

CRSP : 46.10 (-2.45%)
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

NVDA : 146.77 (+0.60%)
ACHR : 5.06 (+0.99%)
CRSP : 46.10 (-2.45%)
IONQ : 30.74 (+6.51%)
CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst a Flat Market

CRISPR Therapeutics (NASDAQ: CRSP) saw a notable increase in its stock price, rising by 3.6% even though there was no significant news directly tied to the company. Meanwhile, its benchmark, the S&P Biotech...

CRSP : 46.10 (-2.45%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The rock star fund investor made a lot of big moves on Thursday.

MELI : 1,895.11 (-1.87%)
CRSP : 46.10 (-2.45%)
AMZN : 200.66 (-1.09%)
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 9.52 (-0.73%)
ESPR : 2.39 (-0.83%)
CRSP : 46.10 (-2.45%)
LSTA : 2.92 (-0.34%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.52 (-0.73%)
AVIR : 3.16 (+0.32%)
CRSP : 46.10 (-2.45%)
APLS : 26.70 (-2.87%)
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...

BEAM : 24.09 (-1.63%)
FOLD : 9.52 (-0.73%)
AVIR : 3.16 (+0.32%)
CRSP : 46.10 (-2.45%)
3 Companies Building Tomorrow's Game-Changing Technologies

These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.

SERV : 8.63 (-1.26%)
CRSP : 46.10 (-2.45%)
RKLB : 20.07 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 49.21
2nd Resistance Point 48.56
1st Resistance Point 47.91
Last Price 46.10
1st Support Level 46.61
2nd Support Level 45.96
3rd Support Level 45.31

See More

52-Week High 91.10
Fibonacci 61.8% 72.89
Fibonacci 50% 67.26
Fibonacci 38.2% 61.63
Last Price 46.10
52-Week Low 43.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar